Ipsen’s partner Exelixis announces clinical collaboration with Bristol Myers Squibb for late-stage combination trial in first-line renal cell carcinoma.

Putting our purpose to the test: what we and the community are learning from our FOP trials

Ipsen at ESMO 2020: our vision, commitment and top three oncology priorities to better serve patients

Executive Leadership Team Announcement

Ipsen announces 3.1% Group Sales Growth, reinstates 2020 guidance